Spots Global Cancer Trial Database for exemestane 25 mg
Every month we try and update this database with for exemestane 25 mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer | NCT03024580 | Breast Neoplasm | Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M... | - | Instituto Nacional de Cancer, Brazil | |
| Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients | NCT02646735 | Breast Cancer | Fulvestrant 500... Exemestane 25 m... | - | ChineseAMS | |
| A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer | NCT03024580 | Breast Neoplasm | Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M... | - | Instituto Nacional de Cancer, Brazil | |
| A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer | NCT03024580 | Breast Neoplasm | Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M... | - | Instituto Nacional de Cancer, Brazil | |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | NCT03874325 | Breast Cancer Hormone Recepto... | Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients | NCT02646735 | Breast Cancer | Fulvestrant 500... Exemestane 25 m... | - | ChineseAMS | |
| Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | NCT05150652 | Breast Cancer HER2-negative B... Node-negative B... Breast Carcinom... | Anastrozole 1mg Letrozole 2.5mg Exemestane 25 m... Tamoxifen | 18 Years - 99 Years | University of Kentucky | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | NCT03874325 | Breast Cancer Hormone Recepto... | Durvalumab Anastrozole 1mg Letrozole 2.5mg Exemestane 25 M... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer. | NCT06364267 | Breast Cancer | Tamoxifen 10 MG Exemestane 25 M... | - | Ente Ospedaliero Ospedali Galliera |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
